Aceto Cp (ACET) 21.53 $ACET
ACETO to Present in June Conferences
GlobeNewswire - Mon May 23, 3:30PM CDT
ACETO Corporation (NASDAQ:ACET), an international company engaged in the marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, today announced it will participate in two investor conferences taking place in June.
ACET: 21.53 (-0.86)
ACETO Reports Fiscal 2016 Third Quarter Results
GlobeNewswire - Thu May 05, 4:00PM CDT
ACETO Corporation (Nasdaq:ACET), an international company engaged in the marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, announced today financial results for the third quarter of fiscal 2016 ended March 31, 2016.
ACET: 21.53 (-0.86)
ACETO Board of Directors Declares Quarterly Cash Dividend
GlobeNewswire - Thu May 05, 10:27AM CDT
ACETO Corporation (NASDAQ:ACET), an international company engaged in the marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, today announced that its Board of Directors has declared a regular quarterly dividend of $0.06 per common share. This quarterly cash dividend will be distributed on June 24, 2016 to shareholders of record as of June 9, 2016.
ACET: 21.53 (-0.86)
Humana (HUM) Q1 Earnings May Disappoint: Stock to Suffer?
Zacks Equity Research - Zacks Investment Research - Mon May 02, 7:51AM CDT
Humana Inc. (HUM) is set to report first-quarter 2016 results on May 4, before the market opens.
ACET: 21.53 (-0.86), BDX: 167.26 (-4.93), AET: 117.94 (-3.06), HUM: 183.72 (-3.59)
DaVita (DVA) Likely to Top Q1 Earnings: Stock to Gain?
Zacks Equity Research - Zacks Investment Research - Mon May 02, 7:08AM CDT
We expect DaVita HealthCare Partners Inc. (DVA) to beat expectations when it reports first-quarter 2016 results on May 4, after the market closes.
ACET: 21.53 (-0.86), BDX: 167.26 (-4.93), DVA: 75.72 (-1.43), BIND: 0.39 (-0.01)
ACETO Corporation Schedules Third Quarter & Fiscal 2016 Financial Results News Release and Conference Call
GlobeNewswire - Thu Apr 21, 7:31AM CDT
ACETO Corporation (NASDAQ:ACET), an international company engaged in the marketing, sales and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, will issue its financial results of operations for the third quarter of fiscal 2016 ended March 31, 2016 after the stock market close on Thursday, May 5, 2016.
ACET: 21.53 (-0.86)
ACETO to Present at the Needham & Company Healthcare Conference
GlobeNewswire - Thu Apr 07, 2:01PM CDT
ACETO Corporation (NASDAQ:ACET), an international company engaged in the marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, today announced that Salvatore Guccione, President and CEO, will present at the Needham & Company Healthcare Conference on April 12, 2016 at 5:00 pm ET at the Westin New York Grand Central Hotel.
ACET: 21.53 (-0.86)
ACETO Subsidiary, Rising Pharmaceuticals, to Launch Lithium Carbonate Extended-release Tablets and Metronidazole Tablets
GlobeNewswire - Wed Mar 23, 8:27AM CDT
ACETO Corporation (NASDAQ:ACET), an international company engaged in the marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, today announced that Rising Pharmaceuticals, Inc., its finished dosage form generics subsidiary, is launching Lithium Carbonate Extended-release Tablets, 300mg, an FDA approved generic version of ANI Pharmaceutical Inc.'s Lithobid, and Metronidazole Tablets, 250mg and 500mg, an FDA approved generic version of G.D. Searle, LLC's Flagyl.
ACET: 21.53 (-0.86)
Aceto Has Returned 13.3% Since SmarTrend Recommendation (ACET)
Comtex SmarTrend(R) - Wed Mar 02, 6:58PM CST
SmarTrend identified a Downtrend for Aceto (NASDAQ:ACET) on December 14th, 2015 at $25.33. In approximately 3 months, Aceto has returned 13.26% as of today's recent price of $21.97.
ACET: 21.53 (-0.86)
20.4% Return Seen to Date on SmarTrend Aceto Call (ACET)
Comtex SmarTrend(R) - Mon Feb 08, 11:37AM CST
SmarTrend identified a Downtrend for Aceto (NASDAQ:ACET) on December 14th, 2015 at $25.33. In approximately 2 months, Aceto has returned 20.41% as of today's recent price of $20.16.
ACET: 21.53 (-0.86)
Aceto posts 2Q profit
Automated Insights - Thu Feb 04, 5:11PM CST
PORT WASHINGTON, N.Y. (AP) _ Aceto Corp. (ACET) on Thursday reported fiscal second-quarter net income of $8.3 million.
ACET: 21.53 (-0.86)
ACETO Reports Fiscal 2016 Second Quarter Results
GlobeNewswire - Thu Feb 04, 4:00PM CST
ACETO Corporation (Nasdaq:ACET), an international company engaged in the marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, announced today financial results for the second quarter of fiscal 2016 ended December 31, 2015.
ACET: 21.53 (-0.86)
ACETO Corporation Schedules Second Quarter & Fiscal 2016 Financial Results News Release and Conference Call
GlobeNewswire - Wed Jan 27, 5:59AM CST
ACETO Corporation (NASDAQ:ACET), an international company engaged in the marketing, sales and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, will issue its financial results of operations for the second quarter of fiscal 2016 ended December 31, 2015 after the stock market close on Thursday, February 4, 2016.
ACET: 21.53 (-0.86)
ACETO to unveil Zolmitriptan Tablets for the treatment of migraine in the US
M2 - Tue Jan 26, 7:53AM CST
Human health products company ACETO Corporation (Nasdaq:ACET) reported on Monday the planned availability of Zolmitriptan Tablets, 2.5mg and 5mg, in the US market for the treatment of migraine with or without aura in adults.
ACET: 21.53 (-0.86)
ACETO Subsidiary, Rising Pharmaceuticals, to Launch Zolmitriptan Tablets
GlobeNewswire - Mon Jan 25, 9:56AM CST
ACETO Corporation (NASDAQ:ACET), an international company engaged in the marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, today announced that Rising Pharmaceuticals, Inc., its finished dosage form generics subsidiary, is launching Zolmitriptan Tablets, 2.5mg and 5mg, an FDA approved generic version of IPR Pharmaceuticals, Inc.'s Zomig.
ACET: 21.53 (-0.86)
LabCorp Poised on Strategic Initiatives, Currency Woes Linger
Zacks Equity Research - Zacks Investment Research - Tue Jan 05, 1:35PM CST
On Jan 5, 2016, we issued an updated research report on Laboratory Corporation of America Holdings (LH).
ACET: 21.53 (-0.86), ABC: 75.43 (-2.12), VWR: 28.83 (-1.25), LH: 128.83 (-2.35)
VWR Corp Poised on Strong Americas Unit, Stable Liquidity
Zacks Equity Research - Zacks Investment Research - Mon Jan 04, 1:15PM CST
On Jan 4, 2015, we issued an updated research report on VWR Corporation (VWR).
ACET: 21.53 (-0.86), ABC: 75.43 (-2.12), VWR: 28.83 (-1.25), CAH: 75.53 (-2.59)
ACETO Subsidiary, Rising Pharmaceuticals, to Launch Olopatadine Hydrochloride Ophthalmic Solution
GlobeNewswire - Mon Dec 07, 1:43PM CST
ACETO Corporation (NASDAQ:ACET), with offices and operations in 10 countries and engaged in the marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, today announced that Rising Pharmaceuticals, Inc., its finished dosage form generics subsidiary, is launching Olopatadine Hydrochloride 0.1% Ophthalmic Solution, an FDA-approved generic version of Alcon Inc.'s Patanol.
ACET: 21.53 (-0.86)
ACETO to Present in June Conferences
GlobeNewswire - Mon May 23, 3:30PM CDT
ACETO Corporation (NASDAQ:ACET), an international company engaged in the marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, today announced it will participate in two investor conferences taking place in June.
ACET: 21.53 (-0.86)
ACETO Reports Fiscal 2016 Third Quarter Results
GlobeNewswire - Thu May 05, 4:00PM CDT
ACETO Corporation (Nasdaq:ACET), an international company engaged in the marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, announced today financial results for the third quarter of fiscal 2016 ended March 31, 2016.
ACET: 21.53 (-0.86)
ACETO Board of Directors Declares Quarterly Cash Dividend
GlobeNewswire - Thu May 05, 10:27AM CDT
ACETO Corporation (NASDAQ:ACET), an international company engaged in the marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, today announced that its Board of Directors has declared a regular quarterly dividend of $0.06 per common share. This quarterly cash dividend will be distributed on June 24, 2016 to shareholders of record as of June 9, 2016.
ACET: 21.53 (-0.86)
Humana (HUM) Q1 Earnings May Disappoint: Stock to Suffer?
Zacks Equity Research - Zacks Investment Research - Mon May 02, 7:51AM CDT
Humana Inc. (HUM) is set to report first-quarter 2016 results on May 4, before the market opens.
ACET: 21.53 (-0.86), BDX: 167.26 (-4.93), AET: 117.94 (-3.06), HUM: 183.72 (-3.59)
DaVita (DVA) Likely to Top Q1 Earnings: Stock to Gain?
Zacks Equity Research - Zacks Investment Research - Mon May 02, 7:08AM CDT
We expect DaVita HealthCare Partners Inc. (DVA) to beat expectations when it reports first-quarter 2016 results on May 4, after the market closes.
ACET: 21.53 (-0.86), BDX: 167.26 (-4.93), DVA: 75.72 (-1.43), BIND: 0.39 (-0.01)
ACETO Corporation Schedules Third Quarter & Fiscal 2016 Financial Results News Release and Conference Call
GlobeNewswire - Thu Apr 21, 7:31AM CDT
ACETO Corporation (NASDAQ:ACET), an international company engaged in the marketing, sales and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, will issue its financial results of operations for the third quarter of fiscal 2016 ended March 31, 2016 after the stock market close on Thursday, May 5, 2016.
ACET: 21.53 (-0.86)
ACETO to Present at the Needham & Company Healthcare Conference
GlobeNewswire - Thu Apr 07, 2:01PM CDT
ACETO Corporation (NASDAQ:ACET), an international company engaged in the marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, today announced that Salvatore Guccione, President and CEO, will present at the Needham & Company Healthcare Conference on April 12, 2016 at 5:00 pm ET at the Westin New York Grand Central Hotel.
ACET: 21.53 (-0.86)
ACETO Subsidiary, Rising Pharmaceuticals, to Launch Lithium Carbonate Extended-release Tablets and Metronidazole Tablets
GlobeNewswire - Wed Mar 23, 8:27AM CDT
ACETO Corporation (NASDAQ:ACET), an international company engaged in the marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, today announced that Rising Pharmaceuticals, Inc., its finished dosage form generics subsidiary, is launching Lithium Carbonate Extended-release Tablets, 300mg, an FDA approved generic version of ANI Pharmaceutical Inc.'s Lithobid, and Metronidazole Tablets, 250mg and 500mg, an FDA approved generic version of G.D. Searle, LLC's Flagyl.
ACET: 21.53 (-0.86)
Aceto Has Returned 13.3% Since SmarTrend Recommendation (ACET)
Comtex SmarTrend(R) - Wed Mar 02, 6:58PM CST
SmarTrend identified a Downtrend for Aceto (NASDAQ:ACET) on December 14th, 2015 at $25.33. In approximately 3 months, Aceto has returned 13.26% as of today's recent price of $21.97.
ACET: 21.53 (-0.86)
20.4% Return Seen to Date on SmarTrend Aceto Call (ACET)
Comtex SmarTrend(R) - Mon Feb 08, 11:37AM CST
SmarTrend identified a Downtrend for Aceto (NASDAQ:ACET) on December 14th, 2015 at $25.33. In approximately 2 months, Aceto has returned 20.41% as of today's recent price of $20.16.
ACET: 21.53 (-0.86)
Aceto posts 2Q profit
Automated Insights - Thu Feb 04, 5:11PM CST
PORT WASHINGTON, N.Y. (AP) _ Aceto Corp. (ACET) on Thursday reported fiscal second-quarter net income of $8.3 million.
ACET: 21.53 (-0.86)
ACETO Reports Fiscal 2016 Second Quarter Results
GlobeNewswire - Thu Feb 04, 4:00PM CST
ACETO Corporation (Nasdaq:ACET), an international company engaged in the marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, announced today financial results for the second quarter of fiscal 2016 ended December 31, 2015.
ACET: 21.53 (-0.86)
ACETO Corporation Schedules Second Quarter & Fiscal 2016 Financial Results News Release and Conference Call
GlobeNewswire - Wed Jan 27, 5:59AM CST
ACETO Corporation (NASDAQ:ACET), an international company engaged in the marketing, sales and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, will issue its financial results of operations for the second quarter of fiscal 2016 ended December 31, 2015 after the stock market close on Thursday, February 4, 2016.
ACET: 21.53 (-0.86)
ACETO to unveil Zolmitriptan Tablets for the treatment of migraine in the US
M2 - Tue Jan 26, 7:53AM CST
Human health products company ACETO Corporation (Nasdaq:ACET) reported on Monday the planned availability of Zolmitriptan Tablets, 2.5mg and 5mg, in the US market for the treatment of migraine with or without aura in adults.
ACET: 21.53 (-0.86)
ACETO Subsidiary, Rising Pharmaceuticals, to Launch Zolmitriptan Tablets
GlobeNewswire - Mon Jan 25, 9:56AM CST
ACETO Corporation (NASDAQ:ACET), an international company engaged in the marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, today announced that Rising Pharmaceuticals, Inc., its finished dosage form generics subsidiary, is launching Zolmitriptan Tablets, 2.5mg and 5mg, an FDA approved generic version of IPR Pharmaceuticals, Inc.'s Zomig.
ACET: 21.53 (-0.86)
LabCorp Poised on Strategic Initiatives, Currency Woes Linger
Zacks Equity Research - Zacks Investment Research - Tue Jan 05, 1:35PM CST
On Jan 5, 2016, we issued an updated research report on Laboratory Corporation of America Holdings (LH).
ACET: 21.53 (-0.86), ABC: 75.43 (-2.12), VWR: 28.83 (-1.25), LH: 128.83 (-2.35)
VWR Corp Poised on Strong Americas Unit, Stable Liquidity
Zacks Equity Research - Zacks Investment Research - Mon Jan 04, 1:15PM CST
On Jan 4, 2015, we issued an updated research report on VWR Corporation (VWR).
ACET: 21.53 (-0.86), ABC: 75.43 (-2.12), VWR: 28.83 (-1.25), CAH: 75.53 (-2.59)
ACETO Subsidiary, Rising Pharmaceuticals, to Launch Olopatadine Hydrochloride Ophthalmic Solution
GlobeNewswire - Mon Dec 07, 1:43PM CST
ACETO Corporation (NASDAQ:ACET), with offices and operations in 10 countries and engaged in the marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, today announced that Rising Pharmaceuticals, Inc., its finished dosage form generics subsidiary, is launching Olopatadine Hydrochloride 0.1% Ophthalmic Solution, an FDA-approved generic version of Alcon Inc.'s Patanol.
ACET: 21.53 (-0.86)
